Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 17/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 12/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | TSPO | P30536 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28465963 | 0.91 | CHRM3 (0.48) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL26529233 | 0.90 | CHRM3 (0.50) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL28477272 | 0.89 | CHRM3 (0.45) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL28465533 | 0.86 | CHRM3 (0.50) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL25906808 | 0.86 | CHRM3 (0.53) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL22747726 | 0.86 | CHRM3 (0.47) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL18229048 | 0.84 | CHRM3 (0.48) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL25908052 | 0.81 | CHRM2 (0.43) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL25908050 | 0.81 | CHRM2 (0.43) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL26529682 | 0.81 | CHRM2 (0.43) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322745-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322745-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-4219485-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-02 | — | — | EP | disclosed |
| CN-111747942-A | Spiro-containing derivative with beta 2 receptor agonistic activity and M receptor antagonistic activity and application thereof in medicine | 四川海思科制药有限公司 | 2020-10-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322745-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CYP3A43, ABCB1, ABCB11 | CHRM3 354/4885CHRM2 1451/4885CHRM1 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.